Vulnerable premature babies needing extra protection against RSV will receive a long-lasting single injection of nirsevimab, ...

A new antibody shot that protects babies against RSV infection could be struggling to gain traction, Philadelphia researchers ...

The risk for severe RSV-related outcomes was effectively reduced among children and infants who received nirsevimab in real-world clinical settings.

Vulnerable premature babies who need extra protection against RSV may receive six months’ protection in a long-lasting single ...

Despite near universal availability of nirsevimab, only 35% of eligible children receive nirsevimab for RSV prophylaxis.

Clinical trials showed nirsevimab was 79% effective against RSV-related lower respiratory infections, rising to 81% for hospitalizations. Simultaneously, a maternal RSV vaccine was introduced.

Despite adequate availability of nirsevimab, only about one third of eligible children receive it for respiratory syncytial virus prophylaxis, with uptake varying by race and other social factors.

Nirsevimab treatment was associated with fewer fevers that were shorter in duration, reduced high-flow oxygen requirements, less antibiotic prescriptions, and lower viral titers.

Nirsevimab, being developed in partnership with AstraZeneca, is the first investigational extended half-life monoclonal antibody (mAb) aiming to protect all infants entering their first RSV season ...

Nirsevimab and the maternal vaccine for respiratory syncytial virus can reduce health care costs and productivity losses associated with RSV but lead to higher overall spending, according to ...

Nirsevimab significantly protected infants against RSV disease in Phase 3 trial Nirsevimab showed a 74.5% reduction in lower respiratory tract infections caused by RSV requiring medical care in ...